Related Experiment Video
Updated: May 21, 2026
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Left ventricular assist devices in heart failure.
1Division of Cardiac Surgery, The Ohio State University, N-831 Doan Hall, 410 W. 10th Avenue, Columbus, OH, USA.
Expert Review of Cardiovascular Therapy
|June 2, 2012
Summary
Left ventricular assist devices (LVADs) significantly improve survival for end-stage heart failure patients, offering a vital alternative to transplantation. These advanced devices enhance quality of life and reduce complications compared to earlier models.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Surgical Technology
Background:
- End-stage heart failure presents a critical unmet medical need with limited survival options.
- Historically, heart transplantation was the sole definitive treatment for advanced heart failure.
- The development of left ventricular assist devices (LVADs) emerged from the necessity to support patients awaiting transplantation.
Purpose of the Study:
- To review landmark studies validating LVADs as a primary therapeutic option for heart failure.
- To provide an overview of currently available LVAD technologies.
- To discuss future advancements and innovations in LVAD therapy.
Main Methods:
- Review of pivotal clinical trials and research demonstrating the efficacy of LVADs.
- Analysis of data comparing outcomes between different generations of LVADs.
- Synthesis of current literature on LVAD technology and patient management.
Main Results:
- LVADs have quadrupled survival rates in patients with end-stage heart failure.
- Modern LVADs exhibit improved biocompatibility, reduced perioperative morbidity, and extended device longevity.
- LVADs have fundamentally transformed the treatment paradigm for advanced heart failure.
Conclusions:
- LVADs represent a significant therapeutic advancement, dramatically improving survival and quality of life for heart failure patients.
- Ongoing technological progress in LVADs promises further enhancements in patient outcomes.
- LVADs are now an established and indispensable component of advanced heart failure management.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...